# Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

> **NCT03126630** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 49 (actual)

## Conditions studied

- Pleural Malignant Mesothelioma

## Interventions

- **BIOLOGICAL:** Anetumab Ravtansine
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03126630
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-04
- **Primary completion:** 2023-05-04
- **Final completion:** 2027-02-25
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126630, "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03126630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*